Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
Hiv-2 integrase variation in integrase inhibitor-naïve adults in senegal, west africa
PLoS ONE, Volume 6, No. 7, Article e22204, Year 2011
Notification
URL copied to clipboard!
Description
Background: Antiretroviral therapy for HIV-2 infection is hampered by intrinsic resistance to many of the drugs used to treat HIV-1. Limited studies suggest that the integrase inhibitors (INIs) raltegravir and elvitegravir have potent activity against HIV-2 in culture and in infected patients. There is a paucity of data on genotypic variation in HIV-2 integrase that might confer intrinsic or transmitted INI resistance. Methods: We PCR amplified and analyzed 122 HIV-2 integrase consensus sequences from 39 HIV-2-infected, INI-naive adults in Senegal, West Africa. We assessed genetic variation and canonical mutations known to confer INI-resistance in HIV-1. Results: No amino acid-altering mutations were detected at sites known to be pivotal for INI resistance in HIV-1 (integrase positions 143, 148 and 155). Polymorphisms at several other HIV-1 INI resistance-associated sites were detected at positions 72, 95, 125, 154, 165, 201, 203, and 263 of the HIV-2 integrase protein. Conclusion: Emerging genotypic and phenotypic data suggest that HIV-2 is susceptible to the new class of HIV integrase inhibitors. We hypothesize that intrinsic HIV-2 integrase variation at "secondary" HIV-1 INI-resistance sites may affect the genetic barrier to HIV-2 INI resistance. Further studies will be needed to assess INI efficacy as part of combination antiretroviral therapy in HIV-2-infected patients. © 2011 Gottlieb et al.
Authors & Co-Authors
Gottlieb., Geoffrey S.
United States, Seattle
University of Washington School of Medicine
Smith, Robert Alexander
United States, Seattle
University of Washington School of Medicine
Badiane, Ndèye Méry Dia
Senegal, Dakar
Centre Hospitalier Universitaire Dakar
Ba, Selly
Senegal, Dakar
Centre Hospitalier Universitaire Dakar
Hawes, Stephen Edward
United States, Seattle
University of Washington School of Public Health and Community Medicine
Touré, Macoumba R.
Senegal, Dakar
Centre Hospitalier Universitaire Dakar
Starling, Alison K.
United States, Seattle
University of Washington School of Medicine
Traoré, Fatou
Senegal, Dakar
Centre Hospitalier Universitaire Dakar
Sall, Fatima
Senegal, Dakar
Centre Hospitalier Universitaire Dakar
Cherne, Stephen L.
United States, Seattle
University of Washington School of Medicine
Stern, Joshua E.
United States, Seattle
University of Washington School of Medicine
Wong, Kim G.
United States, Seattle
University of Washington School of Medicine
Lu, Paul M.
United States, Seattle
University of Washington School of Medicine
Kim, Moon
United States, Seattle
University of Washington School of Medicine
Raugi, Dana Noelle
United States, Seattle
University of Washington School of Medicine
Lam, Airin
United States, Seattle
University of Washington School of Medicine
Mullins, James I.
United States, Seattle
University of Washington School of Medicine
Kiviat, Nancy B.
United States, Seattle
University of Washington School of Medicine
Sow, Papa Salif
Senegal, Dakar
Centre Hospitalier Universitaire Dakar
Statistics
Citations: 24
Authors: 19
Affiliations: 3
Identifiers
Doi:
10.1371/journal.pone.0022204
e-ISSN:
19326203
Research Areas
Genetics And Genomics
Infectious Diseases
Study Locations
Multi-countries
Senegal